346 related articles for article (PubMed ID: 37928039)
1. Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC).
Chen H; Luo W; Lu X; Zhang T
Heliyon; 2023 Nov; 9(11):e20969. PubMed ID: 37928039
[TBL] [Abstract][Full Text] [Related]
2. Role of epigenetics in pancreatic ductal adenocarcinoma.
Pandey S; Gupta VK; Lavania SP
Epigenomics; 2023 Jan; 15(2):89-110. PubMed ID: 36647796
[TBL] [Abstract][Full Text] [Related]
3. Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma.
Gautam SK; Batra SK; Jain M
Mol Cancer; 2023 Jul; 22(1):118. PubMed ID: 37488598
[TBL] [Abstract][Full Text] [Related]
4. The expression of m
Yao Y; Luo L; Xiang G; Xiong J; Ke N; Tan C; Chen Y; Liu X
Gland Surg; 2022 Jan; 11(1):147-165. PubMed ID: 35242677
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study.
Kung HC; Yu J
MedComm (2020); 2023 Apr; 4(2):e216. PubMed ID: 36814688
[TBL] [Abstract][Full Text] [Related]
6. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
[TBL] [Abstract][Full Text] [Related]
7. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
Panchal K; Sahoo RK; Gupta U; Chaurasiya A
Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
[TBL] [Abstract][Full Text] [Related]
8. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
9. Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma.
Zhao X; Liu Y; Li Z; Zheng S; Wang Z; Li W; Bi Z; Li L; Jiang Y; Luo Y; Lin Q; Fu Z; Rufu C
J Cell Mol Med; 2018 Jan; 22(1):655-667. PubMed ID: 28984028
[TBL] [Abstract][Full Text] [Related]
10. Advances in Pancreatic Ductal Adenocarcinoma Treatment.
Anderson EM; Thomassian S; Gong J; Hendifar A; Osipov A
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771675
[TBL] [Abstract][Full Text] [Related]
11. Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma.
Olaoba OT; Yang M; Adelusi TI; Maidens T; Kimchi ET; Staveley-O'Carroll KF; Li G
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672552
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma.
Yang XY; Lu YF; Xu JX; Du YZ; Yu RS
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771172
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies.
Haqq J; Howells LM; Garcea G; Metcalfe MS; Steward WP; Dennison AR
Eur J Cancer; 2014 Oct; 50(15):2570-82. PubMed ID: 25091797
[TBL] [Abstract][Full Text] [Related]
15. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma.
Zhang Y; Huang ZX; Song B
World J Gastroenterol; 2021 Jun; 27(22):3037-3049. PubMed ID: 34168406
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation.
Arnoletti JP; Reza J; Rosales A; Monreal A; Fanaian N; Whisner S; Srivastava M; Rivera-Otero J; Yu G; Phanstiel Iv O; Altomare DA; Tran Q; Litherland SA
PLoS One; 2022; 17(3):e0265725. PubMed ID: 35316296
[TBL] [Abstract][Full Text] [Related]
17. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
18. Upregulated long noncoding RNA LINC01296 indicates a dismal prognosis for pancreatic ductal adenocarcinoma and promotes cell metastatic properties by affecting EMT.
Yuan Q; Zhang Y; Feng L; Jiang Y
J Cell Biochem; 2019 Jan; 120(1):552-561. PubMed ID: 30203487
[TBL] [Abstract][Full Text] [Related]
19. Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches.
Carvalho TMA; Di Molfetta D; Greco MR; Koltai T; Alfarouk KO; Reshkin SJ; Cardone RA
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885243
[TBL] [Abstract][Full Text] [Related]
20. Roles of lncRNAs in pancreatic ductal adenocarcinoma: Diagnosis, treatment, and the development of drug resistance.
Jiang XY; Zhu QC; Zhang XJ; Duan T; Feng J; Sui XB; Sun XN; Mou YP
Hepatobiliary Pancreat Dis Int; 2023 Apr; 22(2):128-139. PubMed ID: 36543619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]